De Novo Ventures of Palo Alto, California, led this round as well as SynergEyes’s series B round. Bio-Star Private Equity Fund joined series A and B investors: Alloy Ventures, Delphi Ventures, InnoCal Venture Capital and Windward Ventures as a new investor.
The new SynergEyes investor, Bio-Star Private Equity Fund, believes the company has the potential to deliver a truly transformational vision correction product.
Jim Ham, CEO for SynergEyes, said: “SynergEyes hybrid contact lenses represent a significant advancement in the contact lens industry and give eye care professionals a one-of-a-kind tool to satisfy one of the largest growing patient categories in the world.”